GFAP Antibody - #BF0345

Fig. 4. Effects of compounds on GFAP and Iba-1 expression in the LPS-induced astrocytes (C6, treated with 10 mg/mL of LPS) and microglia (BV2, treated with 1 mg/mL of LPS). A. Representative fluorescence microscopy images of GFAP immunostaining (Magnification  20). B. Representative fluorescence microscopy images of Iba-1 immunostaining (Magnification  40). C. Histograms show relative changes of GFAP expressed as mean ± SD of the three independent experiments (n ¼ 3). Ctrl. ¼ Control, LPS ¼ Lipopolysaccharide (10 mg/mL); 3, 13, 16 ¼ treatments by compounds 3, 13, 16 (20 mM) along with LPS (10 mg/mL). D. Histograms show relative changes of Iba-1 expressed as mean ± SD of the three independent experiments (n ¼ 3). All the data were analyzed using Image Pro Plus and expressed as a percent of LPS group values (fluorescence intensity). (#) Significant difference (##p < 0.01, ###p < 0.001) vs. control and (*) significant difference (*p < 0.05 and **p < 0.01) vs. LPS.

Figure 3. |Co‑localization of Px1 and GFAP in IP model rats. Px1 (green) and GFAP (red)expression was analyzed using an immunofluorescence assay.Magnification, x200; scale bar, 10 µm. C,control group; IP, incision pain; CBX, carbenoxolone; 10panx, pannexin‑1 mimetic inhibitory peptide; Px1, pannexin 1;GFAP, glial fibrillary acidic protein

Figure 3. |Co‑localization of Px1 and GFAP in IP model rats. Px1 (green) and GFAP (red) expression was analyzed using an immunofluorescence assay. Magnification, x200; scale bar, 10 µm. C, control group; IP, incision pain; CBX, carbenoxolone; 10panx, pannexin‑1 mimetic inhibitory peptide; Px1, pannexin 1;GFAP, glial fibrillary acidic protein.

Figure 2 Emodin reduces spinal cord inflammatory response by inhibiting spinal cord astrocyte activation. Representative (A) hematoxylin and eosin-stained images and (B) inflammation score analysis of the spinal dorsal horn in each group. Scale bar, 20 µm. Representative (C) immunofluorescence staining images of IL-1β and GFAP and (E) quantitative fluorescence intensity analysis (overall magnification, x400; scale bar, 20 µm). (D) Western blot analysis and (F) quantification of the relative grey value of IL-1β and GFAP. Data are presented as the mean ± SD (n=5). *P

Figure 1 Effects of AQP4 on GFAP and p-tau aggregation. (a and b) Histology, qPCR, and Western blot assays verify adenovirus efficiency; (c and d) GFAP and AQP4 and p-tau aggregation (pSer202/pThr205, p-tau) and neuronal marker (NeuN) co-expression were evaluated by Immunofluorescence double staining. *p < 0.05 vs control. All experiments were repeated 3 times. Each group has 7 mice.